Lian B#, Li Z#, Wu N, Li M, Chen X, Zheng H, Gao M, Wang D, Sheng X, Tian H, Si L, Chi Z, Wang X, Lai Y, Sun T, Zhang Q, Kong Y, Long GV, Guo J, Cui C*. Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma.,Annals Of Oncology,2024 Feb;35(2):211-220.

Lian B#, Si L, Chi ZH, Sheng XN, Kong Y, Wang X, Tian H, Li K, Mao LL, Bai X, Tang BX, Yan XQ, Li SM, Zhou L, Dai J, Tang XW, Ran FW, Yao S, Guo J, Cui CL*. Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial,Annals of Oncology,2022 Oct; 33 (10): 1061-1070.

L. L. Mao#, B. Lian#, C.L. Li, X. Bai, L. Zhou, C. L. Cui, Z. H. Chi, X. N. Sheng, X. Wang, B. X. Tang, X. Q. Yan, S. M. Li, Y. Kong, J. Dai, X. T. Wei, J. Li, R. Duan, H. Y. Xu, X. W. Wu, Y. Yang, F. Z. Cheng, C. Zhang, F. Z. Xia, Z. Pang, J. Guo*, L. Si*. Camrelizumab plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial,JAMA Oncology,2023 Aug 1;9(8):1099-1107

Lian B#, Yang Y#, Zheng B, Si L, Zhou L, Chi Z, Mao L, Wang X, Li S, Li J, Wang L, Guo J*, Cui C*. Efficacy and safety of postoperative adjuvant radiotherapy in resected nasal cavity and paranasal sinus mucosal melanoma: A Combined Analysis.,Int J Radiat Oncol Biol Phys,2024 Mar 22:S0360-3016(24)00437-1.

Y. Wang#, B. Lian#, L. Si, L. L. Mao, Z. H. Chi, X. N. Sheng, Y. Kong, X. Wang, X. Bai, X. Q. Yan, S. M. Li, B. X. Tang, J. Dai, L. Zhou, X. T. Wei, C. L. Cui*, J. Guo*. Cumulative incidence and risk factors of brain metastasis for acral and mucosal melanoma patients with stages I–III,European Journal of Cancer,2022 Nov;175:196-203

C. Cui#, B. Lian#, X. Zhang, D. Wu, K. Li, L. Si, Y. Yang, H. Tian, L. Zhou, Z. Chi, X. Sheng, Y. Kong, L. Mao, X. Wang, X. Bai, X. Yan, S. Li, J. Dai, B. Tang, X. Wei, J. E. Gershenwald, C. M. Balch, J. Guo*. An Evidence-Based staging system for mucosal melanoma: A proposal,Ann Surg Oncol,2022 Aug;29(8):5221-5234